#Amrn yahoo conversation update#
#Amrn yahoo conversation archive#
#Amrn yahoo conversation full#

Since the beginning of 2023, we have added a sixth country with Switzerland where we have received individual reimbursement in February. We began the year 2022 negotiating pricing in one market in Europe and ended the year with our product available in five European markets. In 2022, we focused on three main areas, global commercialization, preserving our cash and ensuring that we have the right talent to execute on our new global strategy. Tom, will then discuss our financial results for the fourth quarter and our guidance for 2023, and I will conclude with a look ahead at the remainder of 2023. I will then briefly discuss Amarin's presence at the upcoming ACC meeting. where the team's efforts to stabilize this business is providing the support for our global commercialization efforts.

#Amrn yahoo conversation update#

I will provide an update on our results in the U.S. I will also provide an update on our launch in the UK and where we stand with our plans for global expansion.

Today, I will briefly summarize the actions that we took in 2022 in the spirit of operational excellence to create value over the long term and bring the VASCEPA, VAZKEPA to as many eligible patients as possible across the globe. I'm proud of this team and what we have been able to accomplish together, and I'm excited for what we are able of accomplishing in the future as we continue to execute on our strategy.

Our company is made up of people who come to work every day because they believe in our bold vision to stop cardiovascular disease from being a leading cause of death. while facing increasing genetic competition in the U.S. Amarin is in a unique position as we are building value for a product outside of the U.S. Throughout the remainder of this year, as each piece falls into place, we will be able to see more clearly a successful turnaround and the growing business that we have been building International. We are only beginning to see the results of the actions we took in 2022, and already in 2023. While 2022 was a challenging year for Amarin, it was also a year filled with significant accomplishments that we believe have created the foundation for our future and gives us confidence that 2023 will be a year of tremendous evolution for the company. I will now turn the call over to Karim Mikhail, President and Chief Executive Officer of Amarin. Karim Mikhail, Amarin's President and Chief Executive Officer, will lead our discussion, and Tom Reilly, Amarin's new Chief Financial Officer, will provide a more detailed review of our fourth quarter 2022 financial results.Īfter prepared remarks, we will open the call to your questions.

#Amrn yahoo conversation archive#

An archive of this call will be posted on Amarin's website in the Investor Relations section. This call is intended for investors in Amarin and is not intended to promote the use of VASCEPA/VAZKEPA. Our forward-looking statements do not reflect the potential impact of significant transactions we may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that we may enter into, amend or terminate.įor additional information concerning the risk factors that could cause actual results to differ materially, please see the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2022, which have been filed with the SEC and are now available through the Investor Relations section of our website at We encourage everyone to read these documents. We assume no obligation to update these statements as circumstances change. Actual results or events could differ materially, so you should not place undue reliance on these statements.

We may not achieve our goals, carryout our plans or intentions or meet the expectations disclosed in our forward-looking statements. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. Good morning, everyone, and thank you for joining us. I would now like to turn the conference call over to Lisa DeFrancesco, Senior Vice President, Investor Relations and Corporate Affairs at Amarin.

#Amrn yahoo conversation full#

Operator: Welcome to Amarin Corporation's Conference Call to Discuss its Fourth Quarter and Full Year 2022 Financial Results and Operational Update. Amarin Corporation plc (NASDAQ: AMRN) Q4 2022 Earnings Call Transcript March 1, 2023